Chargement en cours...
Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod
Targeting sphingosine-1-phosphate pathway with orally available immune-modulatory fingolimod (Gilenya™) therapy ameliorates relapsing–remitting multiple sclerosis (RRMS) by decreasing relapse rate as shown in FREEDOMS and TRANSFORMS. Fingolimod has also been shown to be superior to interferon-beta t...
Enregistré dans:
| Publié dans: | Patient Prefer Adherence |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4446999/ https://ncbi.nlm.nih.gov/pubmed/26056436 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PPA.S57354 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|